Close Menu

Bio-Rad

Released this week as a product and a service that uses either catalog or custom arrays, HybSelect initially targets users of the Illumina Genome Analyzer who want to sequence up to 9.5 megabases of genomic DNA.

The partners are deciding whether to run the multiplex test on a microarray or a sequencing platform. Factors in the decision include the complexity of the test and the technical feasibility of multiplexed, targeted resequencing.

Industry Briefs: Mar 5, 2009

Premium

Bruker, NextGen, Sigma-Aldrich, Bio-Rad, Waters, Pressure BioSciences, PSI, Xencor, Pfizer

Both the project and the service are designed to offer cancer patients detailed information about their tumor at a timescale that can help their physicians tailor treatments. However, some experts say the results will not benefit many patients today.

LCS has entered a market varyingly referred to as sequence capture, target enrichment, and sequence enrichment. While the firms playing in this application area cannot agree on a name for it, they all agree that the market has the potential to become, in LCS' words, "very large."

The firm will use the undisclosed amount to optimize the protocols for its genomic-selection application and to start building a sales and marketing force that "will become more visible in the second half of this year," CEO Fred Dom said.

Bio-Rad's Q4 life science sales were hit by cutbacks in capital equipment spending by customers. The firm also was cautious in providing 2009 revenue guidance.

The company claims that compared to other targeted sequence-enrichment methods, its approach leads to more uniform coverage, or less enrichment bias. RainDance said it plans to offer up to 4,000 amplifications in a single tube later this year.

Both companies are offering users of second-generation sequencing systems new tools to select portions of the genome for targeted resequencing but have optimized their products for different sequencing platforms.

Migrations

Premium

Patrick Kelly

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.